In the Flatiron database of PD-L1≥50% NSCLC, among patients receiving first-line ICI monotherapy, KRAS mutations (versus KRAS wt) were associated with significant superior survival (mOS,21.1 vs 13.6 months) (137). Here, KRAS is linked to non-small cell lung carcinoma.